Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Earnings for Vir Biotechnology, Inc. (VIR)
Earnings in 2023 (TTM): $-628,194,000
According to Vir Biotechnology, Inc.'s latest financial reports the company's current earnings (TTM) are $-628,194,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Vir Biotechnology, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-628,194,000 | $-615,061,000 |
| 2022 | $754.28 M | $515.84 M |
| 2021 | $549.8 M | $528.58 M |
| 2020 | $-298,611,000 | $-298,665,000 |
| 2019 | $-174,529,000 | $-174,683,000 |
| 2018 | $-116,364,000 | $-115,884,000 |
| 2017 | $-80,776,000 | $-69,852,000 |